Akero Therapeutics (AKRO) announced results of analyses supporting the clinical activity of efruxifermin in metabolic dysfunction-associated ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback